Company intelligence / Profile preview
Vicore Pharma
Gothenburg, Swedenvicorepharma.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Vicore’s lead candidate buloxibutid (C21), a first-in-class orally available AT2 receptor agonist, has received FDA Fast Track designation for idiopathic pulmonary fibrosis and is in a global Phase 2b trial. The company also develops Almee™, a digital therapeutic for the psychological burden of lung disease patients that has received FDA Breakthrough Device Designation. Early data suggest potential disease-modifying effects and improved patient outcomes in IPF
- Therapeutic areas
- PsychiatryPulmonologyCardiovascular
- Modalities
- small molecules (notably angiotensin II type 2 receptor agonists)digital therapeutics
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Collaborations within the scientific community; specific major pharma partnerships not detailed in public sourcesAcademic collaborations are mentioned but not specified.
Beyond the preview
Go deeper on Vicore Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vicore Pharma.